Microbiome dynamics in immune checkpoint blockade.

Trends Endocrinol Metab

Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. Electronic address:

Published: November 2024

Immune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB. Active research, facilitated by advances in sequencing techniques, is assessing the predominant influence of the intestinal microbiome, as well as the effects of the presence of an intratumoral microbiome. In this review, we describe recent findings from clinical trials, observational studies of human patients, and animal studies on the impact of the microbiome on the efficacy of ICB, highlighting the role of the intestinal and tumor microbiomes and the contribution of methodological advances in their study.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tem.2024.04.013DOI Listing

Publication Analysis

Top Keywords

immune checkpoint
8
checkpoint blockade
8
efficacy icb
8
microbiome
5
microbiome dynamics
4
dynamics immune
4
blockade immune
4
blockade icb
4
icb leading
4
leading immunotherapies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!